Snoring and OSA Treatments in 2026 from GLP-1 Agonists to Surgery

Monday, October 19, 2026

9:30 AM - 10:30 AM PT

Location: 403B

Moderator(s)

Michael Friedman, MD, FACS

Chairman of Otolaryngology-Head and Neck Surgery
Advocate Illinois Masonic Medical Center
Chicago, Illinois, United States

Panelist(s)

Hsin-Ching Lin, MD

Vice Superintendent
Chang Gung Memorial Hospital, Kaohsiung Medical Center
Kaohsiung, Kaohsiung, Taiwan (Republic of China)
Jacob J. Friedman, MD

Dr Jacob Friedman
Chicago ENT
Chicago, Illinois, United States
OJ

Ofer Jacobowitz, MD PhD

Professor
ENT and Allergy Associates
New York, NY, United States

Disclosure(s):

Ofer Jacobowitz, MD PhD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

The audience can expect to see each panelist's approach to a clinical problem with an attempt to achieve consensus in some cases and to explain their reason for controversy in other cases. The presentations will lead to discussions of non-surgical treatment for snoring and sleep apnea including the use of GLP-1 agonists. Minimally invasive treatment options will be discussed based on current literature and the experience of the panelists. Surgical treatment of sleep apnea will be discussed as it relates to presented cases and will be supported by illustrations and videos. Audience participation will be invited to share their experience. The panel is a diverse group representing a broad scope of knowledge and expertise.

Learning Objectives:

Present the data on the use of GLP-1 agonists for OSA treatment.
Present an overview of the decision making for the treatment of snoring and OSA.
Present surgical techniques preferred by the panelists for the treatment of snoring and OSA